Navigation Links
BUMC, BMC receives Clinical and Translational Science Award from NIH
Date:5/29/2008

Boston, MA--The National Institutes of Health (NIH) has awarded one of 14 Clinical and Translational Science Awards (CTSA) for 2008 to a team based at Boston University Medical (BUMC) and Charles River Campuses and Boston Medical Center (BMC). These awards, together with 12 CTSAs awarded in 2007, and 12 awarded in 2006, form the core of an NIH effort to build a national consortium of select centers that will transform how clinical and translational research is conducted, ultimately enabling researchers to provide new and better treatments more efficiently and quickly to patients.

The Boston University Clinical and Translational Science (BU-BRIDGE) Institute will integrate, connect and expand research and programs across traditional academic departments and schools. The institute will be a bridge between disciplines to facilitate interactions by incorporating multiple key programs that support the university-wide commitment to a home for translational research.

The BU-BRIDGE Institute will build on a strong foundation of relationships and trust that presently exists. Moreover, we expect the Institute and its community engagement function to have a transformative effect on clinical and translational research at BUMC by infusing community-based needs and perspectives throughout the Institutes work, said David Center, MD, principal investigator for this project and associate provost for Translational Research, the Gordon and Ruth Snider Professor of Pulmonary Medicine at BUSM and Chief, Pulmonary, Allergy and Critical Care Medicine at BMC.

Importantly, the Institute will provide the administrative structure and process, as well as financial resources, to significantly extend and enhance our successful partnering with our community, Center added.

The CTSA will allow the Institute to build on existing strengths to create an environment linking faculty, trainees and university programs to speed the translation of innovations in medical science to improve maintenance of health and diagnosis and treatment of diseases and share these innovations with other University based Clinical and Translational Science Institute's. The BU-BRIDGE environment will also support the bi-directional development and translation of ideas that begin in the clinic to the BU scientific community and back to identify new ways to improve health and delivery of health care services. Moreover, the Institute will significantly enhance existing partnerships with Boston's community health centers, transforming the conduct of clinical and translational research by infusing it with community based perspectives and needs.

Our program is a confirmation of the close collaboration among the three Boston University Medical Campus schools, Boston Medical Center, the Boston HealthNet Health Centers and Boston Universitys Charles River Campus, said Karen Antman, MD, dean of Boston University School of Medicine and provost of Boston University Medical Campus.

With more than half of NIHs funding allocated for basic research, the CTSA consortium is perfectly poised to help move discoveries in the laboratory to improved patient care. The consortium serves as the bridge in this process that allows researchers to perfect and refine existing treatments through interdisciplinary teams that extend to the clinic and community, said NIH Director Elias A. Zerhouni, MD. Through the consortium, we are better able to leverage expertise and resources across the CTSA institutions, and ultimately maximize NIHs investment in basic research, which should remain a top priority.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8491
Boston University
Source:Eurekalert

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: